Sugi Predict

Sugi Predict / Targets / SLC11A2

SLC11A2

Natural resistance-associated macrophage protein 2 · P49281 · SLC11A2 on Sugi Atlas →

2,992 patent compounds predicted against SLC11A2, 1,577 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2569217 SCHEMBL2569217 0.56 16/20
SCHEMBL2569610 SCHEMBL2569610 0.60 15/20
SCHEMBL2566775 SCHEMBL2566775 0.56 15/20
SCHEMBL563726 SCHEMBL563726 0.63 14/20
SCHEMBL2568090 SCHEMBL2568090 0.60 14/20
SCHEMBL2565743 SCHEMBL2565743 0.59 14/20
SCHEMBL3598602 SCHEMBL3598602 0.78 13/20
SCHEMBL2564086 SCHEMBL2564086 0.60 13/20
SCHEMBL2570992 SCHEMBL2570992 0.53 13/20
SCHEMBL2565341 SCHEMBL2565341 0.52 13/20
SCHEMBL2571006 SCHEMBL2571006 0.52 12/20
SCHEMBL2569224 SCHEMBL2569224 0.58 11/20
SCHEMBL2567610 SCHEMBL2567610 0.56 11/20
SCHEMBL2571163 SCHEMBL2571163 0.55 11/20
SCHEMBL2569355 SCHEMBL2569355 0.49 11/20
SCHEMBL2565049 SCHEMBL2565049 0.68 10/20
SCHEMBL2570758 SCHEMBL2570758 0.66 10/20
SCHEMBL2564205 SCHEMBL2564205 0.49 10/20
SCHEMBL2571481 SCHEMBL2571481 0.49 10/20
SCHEMBL2570816 SCHEMBL2570816 0.48 10/20

Clinical trials — most relevant to SLC11A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer PHASE1/PHASE2COMPLETED
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies PHASE2RECRUITING
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer PHASE1/PHASE2COMPLETED
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer PHASE2NOT_YET_RECRUITING
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer PHASE2WITHDRAWN
A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer PHASE2WITHDRAWN
Immunotherapy Study for Metastatic Renal Cell Cancer PHASE1COMPLETED
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
ImmunoMRI for Assessment of Tumor-associated Macrophages EARLY_PHASE1NOT_YET_RECRUITING
Relation of White Blood Cell Function to Diabetes nanCOMPLETED
Researching Alveolar Macrophage Improvements With Supplements in HIV nanCOMPLETED
Cancer Fusion Hybrids and Desmoplasia nanUNKNOWN
Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection nanCOMPLETED
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer nanCOMPLETED
Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia nanCOMPLETED
The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction nanUNKNOWN
Chloroquine and Post Malaria Anaemia Study nanCOMPLETED
Iron Absorption in The Low Oxygen Exposure and Weight Status (LOWS) Study nanRECRUITING
Exploration of Immunity in Gaucher Disease nanCOMPLETED
Examining Factors That May Influence Resistance to HIV-1 Infection nanCOMPLETED
Molecular Mechanism of Asthma nanWITHDRAWN
Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Renal Transplant Recipients nanCOMPLETED
Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC nanCOMPLETED
Collection of Tissue Samples for Study of Multidrug Resistance nanCOMPLETED
Myeloid Cell Reprogramming in Thyroid Carcinoma nanCOMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features nanUNKNOWN
Determining the Fingerprint of Endotoxin Tolerance nanCOMPLETED
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC11A2 binder may also engage these)

ProteinNameSimilarity
P49282 — 1.000 P49282 →
O54902 — 1.000 O54902 →
A0A2K2BF92 — 0.983 A0A2K2BF92 →
B9H7I1 — 0.983 B9H7I1 →
U5GKY6 — 0.980 U5GKY6 →
Q8H4H5 — 0.978 Q8H4H5 →
P51027 — 0.977 P51027 →
Q9SAH8 — 0.977 Q9SAH8 →
Q653V6 — 0.973 Q653V6 →
Q0D7E4 — 0.972 Q0D7E4 →
P41251 — 0.971 P41251 →
P56436 — 0.971 P56436 →
B9N9Y7 — 0.970 B9N9Y7 →
Q9S9N8 — 0.970 Q9S9N8 →
Q27981 — 0.970 Q27981 →
P49280 — 0.970 P49280 →
P49279 — 0.968 P49279 →
Q9XT74 — 0.967 Q9XT74 →
Q95102 — 0.966 Q95102 →
Q27946 — 0.966 Q27946 →
A1L272 — 0.966 A1L272 →
A0A2K2AIF4 — 0.966 A0A2K2AIF4 →
Q9VE46 — 0.964 Q9VE46 →
O77741 — 0.961 O77741 →
Q5R839 — 0.961 Q5R839 →
P70553 — 0.961 P70553 →
Q6PF45 — 0.960 Q6PF45 →
Q8IVJ1 — 0.960 Q8IVJ1 →
Q3TB48 — 0.958 Q3TB48 →
Q8R070 — 0.958 Q8R070 →